Deramiocel's Promise Brightens Capricor's Outlook, With Strings Attached [Seeking Alpha]
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: Seeking Alpha
Stephen Ayers 7.66K Follower s Follow Play 8min Summary Capricor Therapeutics is advancing deramiocel, an allogeneic cell therapy for DMD-related cardiomyopathy, with a rolling BLA submission and potential FDA approval by 2025. Deramiocel showed significant improvements in upper limb function and LVEF in Phase 2 trials, with ongoing open-label extension trials supporting long-term efficacy and safety. Despite promising prospects, Capricor's upside is limited due to prior commercialization deals, but the stock remains attractively valued with potential milestone payments and royalties. Capricor's strong financial health and cash runway into 2027 support its high-risk/high-reward investment profile, making CAPR a speculative "buy" within a barbell portfolio. JamesBrey Capricor Therapeutics Targets DMD Cardiomyopathy With Deramiocel Capricor Therapeutics NASDAQ: CAPR ) is advancing deramiocel, an allogeneic cell therapy, for DMD-related cardiomyopathy. The compan
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Capricor Therapeutics to Present at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Capricor Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswire
- Capricor wins key EU designations for the lead asset [Seeking Alpha]Seeking Alpha
- Parent Project Muscular Dystrophy Culminates 30th Anniversary with Celebratory "Investing in Every Future" Event [Yahoo! Finance]Yahoo! Finance
- Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency [Yahoo! Finance]Yahoo! Finance
CAPR
Earnings
- 11/13/24 - Miss
CAPR
Sec Filings
- 12/16/24 - Form 4
- 12/4/24 - Form 4
- 11/14/24 - Form 10-Q
- CAPR's page on the SEC website